Transcatheter Aortic Valve Replacement Market (2026-2036)

In terms of volume, the global Transcatheter Aortic Valve Replacement (TAVR) Market was valued at 330.0 thousand procedures in 2025. This market is expected to reach 900.0 thousand procedures by 2036 from an estimated 370.0 thousand procedures in 2026, registering a CAGR of 9.3% during the forecast period (2026-2036).

The transcatheter aortic valve replacement market covers balloon-expandable, self-expanding and mechanically expanded transcatheter aortic valves together with dedicated valves for aortic regurgitation, the delivery systems supplied with them and the accessories used in the procedure, across symptomatic and asymptomatic aortic stenosis, aortic regurgitation and failed surgical or transcatheter valves. The growth of this market is driven by approval in patients without symptoms, by a first approval in aortic regurgitation, by treatment of younger patients in whom lifetime valve management decides the choice, and by procedures moving to outpatient pathways.

Volume grows slightly faster than value in this market, at 9.3% against 8.8%, so average selling price falls from USD 23,030 in 2025 to USD 22,970 in 2026 and USD 22,000 by 2036. The decline is modest because premium valve features and the dedicated regurgitation devices offset tender pressure in the established indications, rather than because prices are holding across the range.

Edwards Lifesciences Corporation announced on 1 May 2025 that the FDA had approved the SAPIEN 3 platform, comprising SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA, for patients with severe aortic stenosis without symptoms, the first approval of transcatheter aortic valve replacement in asymptomatic patients, on the EARLY TAVR trial in which 455 patients were randomised to transcatheter replacement and 446 to guideline-recommended clinical surveillance, with 26.8% of the treated patients and 45.3% of those under surveillance reaching death, stroke or unplanned cardiovascular hospitalisation over a median follow-up of 3.8 years. An absolute difference of 18.5 percentage points means that about six patients are treated to prevent one such event over that period, and the approval moves the eligible population from patients who present with symptoms to patients who do not present at all.

A transcatheter aortic valve is delivered on a catheter, most often through the femoral artery, and deployed inside the diseased native valve without opening the chest or placing the patient on cardiopulmonary bypass. Substitution of open surgery in patients with symptomatic severe aortic stenosis has progressed through the risk categories over fifteen years and is largely complete in the age groups where guidelines support it, so the growth available from taking share from surgery in that population is no longer the main source of expansion. Surgical volumes in those age groups have fallen to the cases where anatomy, concomitant disease or the need for another procedure makes an open operation the better choice, and that residual group is not large enough to sustain the growth rate this market has delivered.

Edwards Lifesciences Corporation announced on 1 May 2025 that the FDA had approved the SAPIEN 3 platform, comprising SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA, for patients with severe aortic stenosis without symptoms, the first approval of transcatheter aortic valve replacement in asymptomatic patients, on the EARLY TAVR trial in which 455 patients were randomised to transcatheter replacement and 446 to guideline-recommended clinical surveillance, with 26.8% of the treated patients and 45.3% of those under surveillance reaching death, stroke or unplanned cardiovascular hospitalisation over a median follow-up of 3.8 years. An absolute difference of 18.5 percentage points over a median 3.8 years means that about six patients are treated to prevent one death, stroke or unplanned cardiovascular hospitalisation, which is a stronger result than the comparison of treatment against watchful waiting has produced in most cardiovascular interventions. Most of the difference arose from unplanned cardiovascular hospitalisation rather than from death, which matters for the payer case because hospitalisation avoided is a cost offset the payer can measure directly.

An asymptomatic patient does not present, which changes what limits growth in that indication. The patient is identified by an echocardiogram performed for another reason, by a murmur noted at an unrelated consultation or by deliberate screening, so volumes depend on echocardiography capacity, on referral pathways from primary care and general cardiology into structural heart programmes, and on the willingness of those programmes to accept patients who feel well. None of those is a device decision. Manufacturers have responded by funding screening and pathway development rather than only by promoting the device, which is a different commercial activity from the one that built the symptomatic market. Field teams are being asked to work with general cardiology and primary care rather than only with implanting centres, which requires a different organisation and a longer payback.

JenaValve Technology announced on 18 March 2026 that the FDA had approved the Trilogy transcatheter heart valve system for symptomatic severe aortic regurgitation in patients at high risk for surgery, on the ALIGN-AR trial, which is the first dedicated transcatheter heart valve approved for that population. Aortic regurgitation had no dedicated transcatheter option because the disease leaves no calcified annulus for a valve to anchor against, so devices designed for stenosis either migrate or leak when used off-label, and a valve designed for anchoring in a non-calcified annulus opens an indication rather than competing within one.

Boston Scientific Corporation announced on 28 May 2025 the discontinuation of the ACURATE transcatheter heart valve platform following the randomised ACURATE IDE trial, with the subsequent literature attributing the outcomes largely to valve underexpansion, described as a procedural problem preventable and correctable by following the manufacturer recommendations rather than a flaw inherent to the device. Withdrawal of one of the four established platforms narrowed the supplier set at the same moment as the indication set widened, which is an unusual combination and leaves the remaining suppliers facing an expanding addressable population with less competition in it.

Treatment of younger patients changes the basis of the decision from procedural outcome to lifetime management. A patient in the sixties receiving a transcatheter valve will outlive it, so the question becomes whether a second valve can be placed inside the first, whether the coronary arteries remain accessible afterwards and how the sequence of interventions is planned over decades. Valve geometry, leaflet position and commissural alignment therefore matter commercially in a way that procedural success rates no longer differentiate.

Five and ten-year follow-up from the low-risk trials arrives on a fixed schedule and cannot be accelerated by investment, and a manufacturer cannot answer a durability question with a better delivery system. That makes the installed clinical experience of the earliest platforms an asset that a newer entrant cannot match at any level of investment, and it is the main reason the market remains concentrated despite the number of approved devices.

Procedures have moved towards same-day discharge and conscious sedation in uncomplicated transfemoral cases, which reduces the cost of the episode, frees inpatient capacity and makes the procedure deliverable in outpatient cardiac facilities rather than only in cardiac surgical centres. That shift widens the set of sites able to perform the procedure, which matters more for volume growth than any device feature, since capacity rather than demand constrains the market in several countries.

Chinese manufacturers supply their domestic market with locally produced valves at prices well below imported devices and have begun to register products elsewhere, while an Indian manufacturer holds a CE mark and has completed a randomised comparison against an established platform. Regional price points consequently differ by a factor that affects reported market value more than it affects procedure numbers, which is why the value and volume growth rates diverge. A reader comparing national markets on revenue will therefore understate activity in Asia and overstate it in North America relative to the number of patients treated.

Reimbursement and programme accreditation rather than clinical evidence set the pace in most health systems. A country decides how many centres may perform the procedure, what volume each must maintain and what the tariff will be, and those decisions determine national volumes more directly than guideline wording does. Expansion into asymptomatic patients therefore requires a tariff and a pathway as well as an approval, and the two do not arrive together. A manufacturer planning a launch in that indication has to forecast against the pace of those decisions rather than against the date of the approval, and that pace differs by country without any clinical reason.